RT Journal Article
SR Electronic
T1 Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.21.22281000
DO 10.1101/2022.11.21.22281000
A1 Wataru Akahata
A1 Takashi Sekida
A1 Takuto Nogimori
A1 Hirotaka Ode
A1 Tomokazu Tamura
A1 Kaoru Kono
A1 Yoko Kazami
A1 Ayaka Washizaki
A1 Yuji Masuta
A1 Rigel Suzuki
A1 Kenta Matsuda
A1 Mai Komori
A1 Amber Morey
A1 Keiko Ishimoto
A1 Misako Nakata
A1 Tomoko Hasunuma
A1 Takasuke Fukuhara
A1 Yasumasa Iwatani
A1 Takuya Yamamoto
A1 Jonathan F Smith
A1 Nobuaki Sato
YR 2022
UL http://medrxiv.org/content/early/2022/11/22/2022.11.21.22281000.abstract
AB BACKGROUND VLPCOV-01 is a lipid nanoparticle-encapsulated self-amplifying RNA (saRNA) vaccine that expresses a membrane-anchored receptor-binding domain (RBD) derived from the SARS-CoV-2 spike protein.METHODS A phase 1 study of VLPCOV-01 was conducted at Medical Corporation Heishinkai OPHAC Hospital, Japan. Participants aged 18 to 55 or ≥65 years who had completed two doses of the BNT162b2 mRNA vaccine 6 to 12 months previously were randomised to receive one intramuscular vaccination of 0·3, 1·0, or 3·0 μg VLPCOV-01, 30 μg BNT162b2, or placebo between February 16, 2022, and March 17, 2022. Solicited adverse events were collected up to 6 days post-administration. Interim immunogenicity analyses included SARS-CoV-2 IgG and neutralising antibody titres. Follow-up for safety and immunogenicity evaluation is ongoing. (The trial is registered: jRCT2051210164).FINDINGS 92 healthy adults were enrolled, with 60 participants receiving VLPCOV-01. No serious adverse events were reported up to 26 weeks, and no prespecified trial-halting events were met. VLPCOV-01 induced robust IgG titres against SARS-CoV-2 RBD protein that were maintained up to 26 weeks in non-elderly participants, with geometric means ranging from 5037 (95% CI 1272–19,940) at 0·3 μg to 12,873 (95% CI 937–17,686) at 3 μg, in comparison to 3166 (95% CI 1619–6191) with 30 μg BNT162b2. Among elderly participants, IgG titres at 26 weeks post-vaccination with 3 μg VLPCOV-01 were 9865 (95% CI 4396–22138) compared to 4183 (95% CI 1436–12180) following vaccination with 30 μg BNT162b2. Pseudovirus neutralising antibody responses were observed against multiple SARS-CoV-2 variants and strongly correlated with anti-SARS-CoV-2 IgG (r=0·950, p<0·001).INTERPRETATION VLPCOV-01 is immunogenic following low dose administration, with anti-SARS-CoV-2 immune responses comparable to BNT162b2. These findings support further development of VLPCOV-01 as a COVID-19 booster vaccine and the potential for saRNA vectors as a vaccine platform.FUNDING Supported by AMED, Grant No. JP21nf0101627.Competing Interest StatementM Komori, A Morey, K Ishimoto and K Matsuda are employees of VLP Therapeutics, Inc.; W Akahata is a board member, an employee and holds stocks in VLP Therapeutics, Inc. and is a management board member of VLP Therapeutics Japan, LLC; J F Smith and M Nakata are employees and hold stocks in VLP Therapeutics. Inc.; T Sekida, N Sato, K Kono and Y Kazami are employees of VLP Therapeutics Japan, LLC; T Hasunuma received a consultation fee from VLP Therapeutics, Inc. for medical advice and consultation on clinical trial design; W Akahata and J F Smith are inventors on related vaccine patent.Clinical TrialjRCT2051210164Funding StatementThis study was funded by Japan Agency for Medical Research and Development (AMED), Grant No. JP21nf0101627Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Medical Corporation Heishinkai OPHAC Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript